InvestSMART

Telix Pharmaceuticals Limited (ASX:TLX)

ALERT: Price-sensitive ASX Announcement for TLX
Current share price for TLX : $16.890 1.44 (9.32%)+
Announcement
Release
14 Apr 2026 4:54PM
Price at Release
$15.450
Full Release
download
Summary
Telix Pharmaceuticals Limited announced an offering of US$550 million convertible notes due 2031, issued by its subsidiary, Telix Pharmaceuticals (Investments) Inc., and guaranteed by Telix and its U.S. counterpart. The new convertible bonds, with a conversion price premium, aim to refinance existing bonds due in 2029 and are listed on the Singapore Exchange. This strategic financial move provides low-cost financing without immediate dilution until conversion. The proceeds will go towards repurchasing existing bonds and general corporate purposes.
Key Points
  • Telix introduces US$550 million convertible notes due 2031.
  • New bonds issued by Telix Pharmaceuticals (Investments) Inc.
  • Bonds guaranteed by Telix and Telix Pharmaceuticals (US) Inc.
  • Initial conversion price set at a premium over current share price.
  • Proceeds intended for repurchasing existing bonds due 2029.
  • Listing of bonds planned on Singapore Exchange.
  • Aim to provide cost-effective, non-dilutive financing until conversion.
  • Managed by J.P. Morgan serving as sole bookrunner and dealer manager.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.